Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...
UK biotech Exscientia has taken a step towards its goal of having four drug candidates in clinical trials next year, after inheriting two precision oncology candidates that emerged from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results